No headlines found.
Globe Newswire (Thu, 18-Dec 4:05 PM ET)
vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 6-Nov 4:15 PM ET)
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.
VTV Therapeutics - Class A trades on the NASDAQ stock market under the symbol VTVT.
As of January 21, 2026, VTVT stock price climbed to $33.05 with 5,818 million shares trading.
VTVT has a market cap of $130.15 million. This is considered a Micro Cap stock.
In the last 3 years, VTVT traded as high as $44.00 and as low as $7.38.
The top ETF exchange traded funds that VTVT belongs to (by Net Assets): VTI, VXF, IWC.
VTVT has outperformed the market in the last year with a return of +136.7%, while the SPY ETF gained +14.9%. In the last 3 month period, VTVT beat the market returning +57.4%, while SPY returned +2.4%. However, in the most recent 2 weeks VTVT has underperformed the stock market by returning -21.3%, while SPY returned -0.6%.
VTVT support price is $29.55 and resistance is $34.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VTVT shares will trade within this expected range on the day.
